BioSpace News Archive

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be available on demand beginning at 6:00 a.m. EST on January 11, 2021. The virtual presentation will be available for 30 days on the Compan

In response to a significant winter storm, the governor of Oklahoma has declared a state of emergency for thirty-nine counties in the state. Blue Cross Blue Shield of Massachusetts (Blue Cross), Inc. is expediting access to care for members who may be affected.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 91,800 shares of its common stock to two new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Indu

As the world faces a new era of emerging and re-emerging infectious diseases, new technologies are paving the way for safer, more effective treatment options. The Self-Contained Negative Pressure Environment (SCONE™) is a new technology developed by SCONE Medical Solutions Inc. (SMS) in collaboration with Mayo Clinic for infectious disea

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11 th at 12:40 p.m. PST / 3:40 p.m. EST . Charles M. Baum , M.D., Ph.D., Mirati’s President and Chief Executive Officer will present at the con

Ministry of Health of Israel has secured 6 million doses and first deliveries expected to begin in January

Two different mRNA vaccines have now shown remarkable effectiveness of about 95% in preventing COVID-19 infection in adults.

SanBio Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology Publication Affirms SanBio’s Approach to Treating Chronic Traumatic Brain Injury Patients

ViewRay, Inc. announced the pricing of an underwritten public offering of 10,310,000 shares of common stock at a price to the public of $4.85 per share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ViewRay.

Neurocrine Biosciences, Inc. will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. Eastern Time on Monday Jan. 11, 2021.